Table 5 NSABP FB-7: pathologic complete response (pCR) rates in 8-gene signature trastuzumab benefit groups
8-Gene trastuzumab benefit prediction group | No. of samples | pCR rate in all arms (%) | Trastuzumab | Neratinib | Trastuzumab plus neratinib |
|---|---|---|---|---|---|
No benefit | 9 | 22 | 1/3 (33%) | 0/5 (0%) | 1/1 (100%) |
Intermediate benefit | 32 | 53 | 4/8 (50%) | 5/10 (50%) | 8/14 (57%) |
Most benefit | 12 | 75 | 4/4 (100%) | 4/7 (57%) | 1/1 (100%) |